House Prioritizes Patient Safety; Rejects “Right-To-Try” Legislation

Washington, D.C.—The House of Representatives tonight rejected legislation that would have changed the process for accessing experimental drugs without including necessary patient safeguards. The Right-to-Try legislation was opposed by the American Cancer Society Cancer Action Network (ACS CAN) along with more than 85 other organizations representing millions of patients.

A statement from ACS CAN President Chris Hansen follows:

“We’re pleased patient concerns over this legislation were heard and reflected in tonight’s vote on the ‘Right to Try’ legislation. Preserving the Food and Drug Administration’s ability to consult on drug dosing, scheduling and administration among other important safety measures for which the agency is uniquely qualified is critical to protecting patients and their access to new therapies.

“We look forward to continuing to work with Congress to identify and develop efficient, effective and safe ways to improve patients’ access to potentially promising new treatments.”